单位：[1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital ,National Clinical Research Center for Respiratory Disease ,Institute of Respiratory Medicine, Chinese Academy of Medical Science ,Peking University Health Science Center, Beijing, People’s Republic of China[2]China National Health Development Research Center, National Health Commission of the People’s Republic of China, Beijing, People’s Republic of China
Background: Indacaterol/glycopyrronium (IND/GLY) is a once-daily dual bronchodilator for long-term treatment of patients with chronic obstructive pulmonary disease (COPD). The efficacy and safety of IND/GLY have been proved before, but the cost-effectiveness is unknown in China. Purpose: This study assessed cost-effectiveness of IND/GLY comparing with salmeterol/ fluticasone (SAL/FLU) and tiotropium. Methods: A patient-level simulation model was established from Chinese payer perspective. Patient parameters were randomly simulated through resampling from parameter distributions based on clinical trials and China-specific cost data to represent individual level health state and health state transitions in the model. We simulated patient-level health state, costs, life years (LYs) and quality-adjusted life years (QALYs) of whole life horizon to evaluate the cost-effectiveness of IND/GLY comparing with SAL/FLU and tiotropium respectively. Results: Comparing with SAL/FLU, IND/GLY resulted in 0.384 LYs and 0.255 QALYs gained. The incremental cost-effectiveness ratio (ICER) is -35,822 CNY/LY and the incremental costutility ratio (ICUR) is -53,834 CNY/QALY for IND/GLY versus SAL/FLU. Comparing with tiotropium, IND/GLY resulted in 0.232 LYs and 0.146 QALYs gained. The ICER is 39,729 CNY/ LY and the ICUR is 63,246 CNY/QALY for IND/GLY versus tiotropium. Conclusion: This study found that dual bronchodilator IND/GLY is cost-effective for stable COPD treatment in China from Chinese payer's perspective.
第一作者单位：[1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital ,National Clinical Research Center for Respiratory Disease ,Institute of Respiratory Medicine, Chinese Academy of Medical Science ,Peking University Health Science Center, Beijing, People’s Republic of China
通讯作者：
通讯机构：[1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital ,National Clinical Research Center for Respiratory Disease ,Institute of Respiratory Medicine, Chinese Academy of Medical Science ,Peking University Health Science Center, Beijing, People’s Republic of China[*1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital ,National Clinical Research Center for Respiratory Disease ,Peking University Health Science Center ,Institute of Respiratory Medicine, Chinese Academy of Medical Science, Peking University Health Science Center, No. 2 Yinghua East Street, Chaoyang District, Beijing, People’s Republic of China
推荐引用方式(GB/T 7714)：
Gong Shiyi,Hu Hao,Zhao Kun,et al.Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China[J].INTERNATIONAL JOURNAL of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.2021,16:433-441.doi:10.2147/COPD.S276476.
APA：
Gong, Shiyi,Hu, Hao,Zhao, Kun&Yang, Ting.(2021).Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China.INTERNATIONAL JOURNAL of CHRONIC OBSTRUCTIVE PULMONARY DISEASE,16,
MLA：
Gong, Shiyi,et al."Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China".INTERNATIONAL JOURNAL of CHRONIC OBSTRUCTIVE PULMONARY DISEASE 16.(2021):433-441
